PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
April 15, 20240 citations

Supplementary Figure S4 from A Phase I Study of Acapatamab, a Half-life Extended, PSMA-Targeting Bispecific T-cell Engager for Metastatic Castration-Resistant Prostate Cancer

View Full Paper
TDTanya B. DorffLHLisa G. HorvathKAKaren A. Autio

Key Points

Key points are not available for this paper at this time.

Abstract

Acapatamab-induced PSA response in patients who received prior lutetium-PSMA therapy

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Dorff et al. (2024) studied this question.

synapsesocial.com/papers/68e6f2aeb6db64358766d823https://doi.org/10.1158/1078-0432.25603405
Ask AI
Helpful
Bookmark
Share
View Full Paper